熱門資訊> 正文

Zai Lab获得用于治疗神经内分泌癌的ADC的孤儿药地位

2026-08-03 21:28

The US FDA has granted Orphan Drug status to Zai Lab's (LAB) antibody-drug conjugate zocilurtatug pelitecan for neuroendocrine carcinomas.
The asset previously received Fast Track designation for other indications, including small cell lung cancer.
Zoci targets Delta-like ligand 3 (DLL3), which is overexpressed in many neuroendocrine carcinomas.

More on Zai Lab

Zai Lab: A Speculative Bet On Global Oncology, With A Greater China Bag Attached
Zai Lab Limited 2026 Q1 - Results - Earnings Call Presentation
Zai Lab Limited (ZLAB) Q1 2026 Earnings Call Transcript
Pfizer, Zai Lab win China nod for cervical cancer therapy Tivdak
Mid-cap healthcare stocks ranked by quant ratings after earnings season

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。